Trials / Completed
CompletedNCT00726648
CDP323 Biomarker Study
Double-blind, Placebo-controlled, Randomized, Parallel-group Study in Subjects With Relapsing Forms of Multiple Sclerosis to Evaluate the Effects of Different CDP323 Doses on Biomarker Patterns as Well as on Safety and Tolerability.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Comparison of the effects of different CDP323 doses given over a period of four weeks on blood biomarkers in subjects with relapsing forms of multiple sclerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CDP323 | 50mg capsules, 100mg bid for 4 weeks |
| DRUG | CDP323 | 250mg capsules, 500mg bid for 4 weeks |
| DRUG | CDP323 | 250mg capsules, 1000mg bid for 4 weeks |
| DRUG | CDP323 | 250mg capsules, 1000mg daily for 4 weeks |
| DRUG | Placebo | placebo capsules for 4 weeks |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2008-08-01
- Last updated
- 2011-09-12
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00726648. Inclusion in this directory is not an endorsement.